Scientific Sessions 2025  /  Pharmacologic Management of Heart Failure and Cardiomyopathy  /  The impact of Sodium Glucose Cotransporter 2 Inhibitors in hypertrophic cardiomyopathy: systematic review and meta-analysis
Logo

American Heart Association

  66
  0

Final ID: MP2037

The impact of Sodium Glucose Cotransporter 2 Inhibitors in hypertrophic cardiomyopathy: systematic review and meta-analysis

Abstract Body (Do not enter title and authors here): Background: Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i) are well-established therapies for heart failure and type 2 diabetes mellitus. However, the impact of SGLT2i in patients with hypertrophic cardiomyopathy (HCM) remains unclear. Therefore, we conducted a systematic review and meta-analysis to evaluate the effectiveness of SGLT2i in patients with HCM.

Methods: According to PRISMA guidelines, a systematic search was conducted in PubMed, Embase and Cochrane databases for studies evaluating the use of SGLT2i in patients with HCM. The primary endpoints were heart failure (HF) hospitalization and all-cause mortality. Results are reported as odds ratio (OR) with 95% confidence intervals (CI). Statistical analyses were performed using the Review Manager with a random-effects model. Heterogeneity was assessed using the I2 statistic.

Results: Three studies comprising a total of 5,046 patients were included, of whom 2,523 (50.00%) received SGLT2 inhibitors. Overall, 70.70% of patients were male, and the median age was 64.8 years. At a median follow-up of 22.3 months, SGLT2i was associated with a significantly lower risk of all-cause mortality (OR: 0.31; 95%CI: 0.25 to 0.37; P<0.00001; I2=0%; Figure 1) compared to standard of care. There was no significant difference in HF hospitalization (OR: 0.68; 95%CI: 0.43 to 1.06; P = 0.05; I2=66%; Figure 2) between SGLT-2i and standard of care groups.

Conclusion: In this meta-analysis, primarily based on retrospective data SGLT2 inhibitors were associated with a significant reduction in all-cause mortality in patients with HCM. These findings highlight the potential benefit of SGLT2i on cardiovascular outcomes but further dedicated randomized controlled trials are warranted to confirm these results.
  • Mendes Afonso, Luisalice  ( Federal University of Cariri , Barbalha , Brazil )
  • Chendey, Taras  ( Uzhhorod National University , Uzhhorod , Ukraine )
  • Modumudi, Sravani  ( Kamineni Academy of Medical Sciences and Research Center , Hyderabad , India )
  • Bianchi, Lorenzo  ( University of Genoa , Genoa , Italy )
    • Author Disclosures:
    Luisalice Mendes Afonso: DO NOT have relevant financial relationships | Taras Chendey: DO NOT have relevant financial relationships | Sravani Modumudi: No Answer | Lorenzo Bianchi: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Pharmacologic Management of Heart Failure and Cardiomyopathy

Monday, 11/10/2025 , 10:45AM - 12:00PM

Moderated Digital Poster Session

More abstracts on this topic:
A novel Urocortin-2 analog COR-1167 corrects cardiac and renal dysfunction on top of Empagliflozin in a rat model of acute decompensated heart failure

Stephan Yohan, Corruble Clement, Charrier Lucie, Nicol Lionel, Kowala Mark, Ozoux Marie-laure, Lawson Francesca, Janiak Philip, Mulder Paul

A Hypertrophic Cardiomyopathy Polygenic Score Modifies Penetrance of Pathogenic Hypertrophic and Dilated Cardiomyopathy Variants in Opposite Directions

Abramowitz Sarah, Hoffman-andrews Lily, Depaolo John, Judy Renae, Owens Anjali, Damrauer Scott, Levin Michael

4364921_File000004.jpg
4364921_File000004.jpg
4364921_File000005.jpg
4364921_File000005.jpg
You have to be authorized to contact abstract author. Please, Login
Not Available